View ValuationSandoz Group 향후 성장Future 기준 점검 3/6Sandoz Group (는) 각각 연간 16.9% 및 5.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 17.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 17.7% 로 예상됩니다.핵심 정보16.9%이익 성장률17.18%EPS 성장률Pharmaceuticals 이익 성장10.5%매출 성장률5.1%향후 자기자본이익률17.71%애널리스트 커버리지Good마지막 업데이트08 Jul 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jul 01Sandoz Group AG Receives US FDA File Acceptances for Generic Tirzepatide Autoinjector ApplicationsSandoz Group AG received US FDA file acceptances for generic tirzepatide autoinjector applications. Proposed generic tirzepatide was developed in-house by Sandoz. Applications address same indications covered by reference medicines, including type-2 diabetes and weight management. The ANDAs seek approval for an in-house Sandoz generic version of the tirzepatide autoinjector, a generic gastric inhibitory polypeptide receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Both applications, which were filed under the FDA's generic pathway, address all indications of the reference medicines, Mounjaro and Zepbound. For Mounjaro, this would be as an adjunct to diet and exercise to improve glycemic control in adults and paediatric patients 10 years of age and older with type 2 diabetes mellitus. For Zepbound, this would be in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in obese or overweight adults in the presence of at least one weight-related comorbid condition and to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity for weight management. Subject to FDA approval, Sandoz tirzepatide could be one of the first generic tirzepatide products available for patients in the US on market formation. Generic tirzepatide was developed in-house at Sandoz, combining the Company's expertise in small molecule and device development with its biosimilar expertise for advanced techniques. The GLP-1 treatment area represents a long-term market opportunity, complementing the broader growth outlook for biosimilar and generic medicines. Reference medicines with a combined value of more than USD 650 billion are expected to lose patent protection over the next decade. Sandoz is developing a competitive GLP-1 pipeline across key global markets, addressing each opportunity with a mix of internal capabilities and strategic external partnerships across development and manufacturing. Sandoz is committed to helping millions of patients access critical and potentially life-changing medicines sustainably and affordably, with a leading global portfolio comprising 1,300 quality generics and a further 400 generic assets in various stages of development.Board Change • May 21High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공고 • May 16Sandoz Group AG Confirms European Commission Approval for Biosimilars Bysumlog® (Insulin Lispro) and Dazparda® (Insulin Aspart), Strengthening Position in DiabetesSandoz Group AG confirms that the European Commission has granted marketing authorisation for Bysumlog (insulin lispro) and Dazparda (insulin aspart). The two biosimilar insulins, for injection in prefilled pens, are developed by Gan & Lee Pharmaceuticals. Bysumlog is approved for the treatment and initial stabilisation of diabetes mellitus in adults and children1, while Dazparda is approved for the treatment of diabetes mellitus in adults, adolescents and children aged one year or more . Both biosimilar insulins have equivalent efficacy and comparable safety to their respective reference medicines, Humalog® and NovoRapid® . Following these approvals, Bysumlog and Dazparda have the potential to increase competition, improve affordability and expand access to insulin treatment options for millions of people living with diabetes across Europe. Diabetes is a chronic condition that occurs when either the pancreas does not produce enough insulin, a hormone that regulates blood glucose, or when the body cannot effectively use the insulin it produces. The disease and its complications can cause blindness, kidney failure, heart attacks, stroke and lower-limb amputation in some patients . An estimated 66 million adults aged 20–79 in Europe live with diabetes and this is projected to rise by 10% to 72 million by 2050, with related healthcare expenditure approaching USD 200 billion . Sandoz entered into an agreement with Gan & Lee in December 2018 to commercialise biosimilar versions of the insulins aspart, lispro and glargine. Under the terms of the agreement, Sandoz will commercialise in Europe and other key territories around the world, while Gan & Lee is responsible for development, manufacturing and supply. The approvals contribute to the continued Sandoz leadership and pioneering legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006. They underscore the company’s commitment to help millions of patients access biologic medicines sustainably and affordably through a global portfolio of 13 biosimilars, supported by an industry-leading pipeline. They further strengthen the Sandoz position in diabetes, while representing another step towards the overall strategic objective of capitalising on a projected approximately USD 320 billion biosimilar market opportunity over the next 10 years .Board Change • May 05High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공고 • Mar 09Sandoz Group AG, Annual General Meeting, Apr 09, 2026Sandoz Group AG, Annual General Meeting, Apr 09, 2026, at 10:00 W. Europe Standard Time.New Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Austrian stocks, typically moving 4.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Reported Earnings • Feb 28Full year 2025 earnings releasedFull year 2025 results: EPS: US$2.12. Revenue: US$11.2b (up 7.4% from FY 2024). Net income: US$914.0m (up US$914.0m from FY 2024). Profit margin: 8.2% (up from 0% in FY 2024). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in Europe.공고 • Feb 27Sandoz Group AG announces Annual dividend, payable on April 15, 2026Sandoz Group AG announced Annual dividend of CHF 0.8000 per share payable on April 15, 2026, ex-date on April 13, 2026 and record date on April 14, 2026.공고 • Feb 26Sandoz Confirms European Commission Approval for Ranluspec®? (Ranibizumab)Sandoz confirmed that the European Commission has granted marketing authorization for Ranluspec. Ranluspec is developed, manufactured and registered by Lupin and was approved based on the review of a comprehensive data package. Ranluspec is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular edema, proliferative diabetic retinopathy, visual impairment due to macular edema secondary to retinal vein occlusion and visual impairment due to choroidal neovascularization. Ranluspec has equivalent efficacy and comparable safety to its reference medicine, Lucentis®?. Around four million people are estimated to have neovascular age-related macular degenerization in France, Germany, Italy, Spain, the UK, the US and Japan3, and between 20% and 35% of people with diabetes in Europe will develop diabetic retinopathy4. The approval paves the way for an expected launch of Ranluspec in the second half of 2026. The announcement builds on the continuing leadership and pioneering legacy Sandoz has established in biosimilars, which began with the introduction of the first biosimilar, Omnitrope®? (somatropin), in 2006. It strengthens the company's position in ophthalmology, following the launch of Afqlir®? (aflibercept) in Europe in 2025 and also represents another step towards the overall Sandoz strategic objective of capitalizing on a projected USD 320 billion biosimilar-market opportunity over the next 10 years. Sandoz and Lupin announced a commercial partnership in August 2025 for the development and commercialization of a ranibizumab biosimilar. Under the terms of the agreement, Sandoz holds exclusive commercialization rights for Ranluspec across the European Union, excluding Germany, and semi-exclusive rights in France. Sandoz is commercializing Epruvy®? (ranibizumab) in Germany under a separate agreement. Lucentis®? is a registered trademark of Genentech Inc.공고 • Feb 21Sandoz Group AG Receives US FDA Approval to Expand Enzeevu (Aflibercept-Abzv) Label for Multiple Retinal IndicationsSandoz Group AG on February 18, 2026 announced that the US Food and Drug Administration (FDA) has approved an expanded label for Enzeevu (aflibercept-abzv), to include multiple retinal indications. Enzeevu was originally approved by the FDA for the treatment of neovascular (wet) age-related macular degeneration (nAMD) in August 2024. The most recent approval expands the Enzeevu label indications to include macular edema following retinal vein occlusion (RVO), diabetic retinopathy (DR) and diabetic macular edema (DME), along with the previously approved indication of nAMD. This expansion offers retina specialists a clinically-proven aflibercept biosimilar option to treat more patients across these retinal diseases. Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably, with a leading global portfolio comprising 13 biosimilars and a further 27 assets in various stages of development. This approval strengthens the company’s position in ophthalmology, following the acquisition of the US biosimilar Cimerli (ranibizumab-eqrn) in 2024 and the European launch of Afqlir (aflibercept) in 2025. It also represents another step towards the overall strategic objective of capitalizing on a projected approx. USD 320 billion biosimilar market opportunity over the next 10 years . Enzeevu is expected to launch in the US in the fourth quarter of 2026, or earlier under certain circumstances.Board Change • Feb 05High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공고 • Jan 16Sandoz Confirms European Commission Approval of Ondibta® (Insulin Glargine)Sandoz confirmed that the European Commission has granted marketing authorization for Ondibta® (insulin glargine), a solution for injection in a pre-filled pen developed and registered by Gan & Lee Pharmaceuticals. Ondibta® is approved for the treatment of diabetes mellitus in adults, adolescents and children aged two years and above and is confirmed to match the reference medicine, Lantus® SoloStar® insulin pen, in terms of safety, quality and efficacy. The approval paves the way for an expected launch of Ondibta® by early 2027, which has the potential to increase competition, improve affordability and enhance access to insulin treatment options for people living with diabetes in Europe. Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin, a hormone that regulates blood glucose, or when the body cannot effectively use the insulin that it produces. It can cause blindness, kidney failure, heart attacks, stroke and lower limb amputation. According to latest estimates, there are 66 million adults aged 20-79 living with diabetes in Europe, a figure that is expected to increase 10% by 2050 to 72 million, with related healthcare expenditure approaching USD 200 billion. Sandoz entered into an agreement with Gan & Lee in December 2018 to commercialize biosimilar versions of the insulins glargine, lispro and aspart. Under the terms of the agreement, Sandoz will commercialize in Europe and other key territories around the world, while Gan & Lee is responsible for development, registration, manufacturing and supply. The approval builds on the continuing Sandoz leadership and pioneering legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006. It also strengthens the Sandoz position in diabetes, while representing another step towards the overall strategic objective of capitalizing on a projected USD 320 billion biosimilar-market opportunity over the next 10 years. Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably, with a leading global portfolio comprising 13 biosimilars and a further 27 assets in various stages of development.Board Change • Jan 07High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Dec 15High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공고 • Dec 03Sandoz Launches Denosumab Biosimilars in Europe, Providing Affordable Treatment Option for Cancer-Related Bone Disease and Osteoporosis for Millions of PatientsSandoz announced the European launch of Wyost ® (denosumab 120 mg) and Jubbonti ® (denosumab 60 mg). The medicines are among the first denosumab biosimilars to launch in Europe and are approved by the European Commission to treat all indications of the reference medicines, Xgeva ® (denosumab 120 mg) and Prolia (denosumab 60 mg). Wyost ® is approved for the treatment of cancer-related bone disease and Jubbonti ® is approved to treat osteoporosis. Wyost ® and Jubbonti ® represent key value drivers for Sandoz and the European launch marks the next major step in advancing the company’s growth strategy. It builds on other key biosimilar launches this year including Wyost ® and Jubbonti ® in the US and the recent launches of Tyruko ® (natalizumab) in the US and Afqlir ® (aflibercept) in Europe. Close to one quarter (4.14 million) of all newly reported cancer cases globally occur in Europe and cancer remains a leading cause of premature death for people aged 30-69 years in most European countries. Nearly all types of cancer can spread to the bone and cause pain and fractures, but cancers that often metastasize there include breast, lung and prostate Wyost ® and Jubbonti ® will be launched across Europe today, with additional rollouts to follow throughout 2026. This launch builds on the continuing Sandoz leadership and pioneering legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006. It further expands the company’s presence in a global reference-medicine market worth a combined ~USD 6.6 billion and reinforces its established position in oncology and immunology. Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably, with a leading global portfolio comprising 13 biosimilars and a further 27 assets in various stages of development. Wyost ® (denosumab 120 mg) and Jubbonti ® (denosumab 60 mg) have been developed as biosimilars to the reference medicines Xgeva and Prolia, respectively. Both medicines contain the same active ingredient (denosumab), a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to RANKL, preventing activation of its receptor, RANK, on the surface of osteoclast precursors and osteoclasts. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function and survival, thereby decreasing bone resorption in cortical and trabecular bone. Wyost ® is indicated in Europe to prevent skeletal related events (SREs; pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone, and to treat adults and skeletally mature adolescents with a giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Jubbonti ® is indicated in Europe to treat osteoporosis in postmenopausal women and in men at increased risk of fractures, bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures and bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.공고 • Nov 25Sandoz Group AG Launches Afqlir®? (aflibercept) in Europe, Providing Affordable Treatment Option for Patients with Retinal DiseasesSandoz Group AG announced the European launch of Afqlir ® (aflibercept). Afqlir ®, a 2 mg vial kit and pre-filled syringe for intravitreal injection, was approved by the European Commission in November 2024 for the same indications in adult patients as the reference medicine, Eylea ®, namely the treatment of various retinal diseases to prevent disease-related blindness. Studies confirm that Afqlir ® matches the reference medicine in efficacy, safety and pharmacokinetics. Aflibercept is considered a gold standard for treating various neovascular retinal diseases. Conditions like age-related macular degeneration (AMD), retinal vein occlusion (RVO) and diabetic macular edema (DME) are leading causes of vision loss and their global prevalence is increasing. A subtype of age-related macular degeneration (AMD), nAMD is characterized by vision loss in the central zone and is a leading cause of vision impairment in patients over 65 years of age. Although nAMD represents about 10 to 20 percent of all AMD cases, it accounts for 90 percent of severe vision loss linked to AMD. In France, Germany, Italy, Spain, the UK, the US and Japan, around 4.0 million people are estimated to have nAMD. Of these, 2.8 million are diagnosed but only 2.0 million receive treatment. Afqlir ® will be launched across Europe, beginning in the UK, followed by other major markets such as Germany and France, with additional rollouts to follow in 2026. Afqlir ® is one of several biosimilar value drivers for Sandoz and this launch represents another step in advancing the company’s growth strategy, building on major launches this year including Tyruko ® (natalizumab) and Wyost ® (denosumab) and Jubbonti ® (denosumab) in the US. Sandoz is committed to helping million of patients access critical and potentially life-changing biologic medicines sustainably and affordably, with a leading global portfolio comprising 13 biosimilars and a further 27 assets in various stages of development. The launch builds on the existing Sandoz leadership and legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006, and expands the company’s presence in the ~USD 15 billion anti-VEGF ophthalmology market. In September 2025, Sandoz also announced that it had reached an agreement with Regeneron Pharmaceuticals Inc. to resolve all patent disputes between the two companies relating to the US Food and Drug Administration (FDA)-approved aflibercept biosimilar, clearing the path for the launch of Enzeevu™ (aflibercept-abzv) in the US by the end of 2026.공고 • Nov 16Sandoz Group AG to Report First Half, 2026 Results on Aug 05, 2026Sandoz Group AG announced that they will report first half, 2026 results on Aug 05, 2026Board Change • Oct 30High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.이익 및 매출 성장 예측WBAG:SDZ - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202813,3121,8961,6352,2151312/31/202712,7071,6891,3691,9911412/31/202612,1141,3677531,5451412/31/202511,1579148361,594N/A9/30/202510,8725715481,272N/A6/30/202510,587227259950N/A3/31/202510,486114168803N/A12/31/202410,384N/A76656N/A9/30/202410,248-4-28581N/A6/30/202410,111-8-133506N/A3/31/202410,04535-195434N/A12/31/20239,97977-258362N/A9/30/20239,770345136664N/A6/30/20239,561613530966N/A3/31/20239,4347316791,095N/A12/31/20229,3068488281,223N/A12/31/20219,6789081,0001,354N/A12/31/20209,6584628131,098N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: SDZ 의 연간 예상 수익 증가율(16.9%)이 saving rate(2.3%)보다 높습니다.수익 vs 시장: SDZ 의 연간 수익(16.9%)이 Austrian 시장(11.2%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: SDZ 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: SDZ 의 수익(연간 5.1%)이 Austrian 시장(연간 4.6%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: SDZ 의 수익(연간 5.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: SDZ의 자본 수익률은 3년 후 17.7%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/15 09:24종가2026/07/15 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Sandoz Group AG는 36명의 분석가가 다루고 있습니다. 이 중 14명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Emily FieldBarclaysJames GordonBarclaysSidhartha ModiBarclays33명의 분석가 더 보기
공고 • Jul 01Sandoz Group AG Receives US FDA File Acceptances for Generic Tirzepatide Autoinjector ApplicationsSandoz Group AG received US FDA file acceptances for generic tirzepatide autoinjector applications. Proposed generic tirzepatide was developed in-house by Sandoz. Applications address same indications covered by reference medicines, including type-2 diabetes and weight management. The ANDAs seek approval for an in-house Sandoz generic version of the tirzepatide autoinjector, a generic gastric inhibitory polypeptide receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Both applications, which were filed under the FDA's generic pathway, address all indications of the reference medicines, Mounjaro and Zepbound. For Mounjaro, this would be as an adjunct to diet and exercise to improve glycemic control in adults and paediatric patients 10 years of age and older with type 2 diabetes mellitus. For Zepbound, this would be in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in obese or overweight adults in the presence of at least one weight-related comorbid condition and to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity for weight management. Subject to FDA approval, Sandoz tirzepatide could be one of the first generic tirzepatide products available for patients in the US on market formation. Generic tirzepatide was developed in-house at Sandoz, combining the Company's expertise in small molecule and device development with its biosimilar expertise for advanced techniques. The GLP-1 treatment area represents a long-term market opportunity, complementing the broader growth outlook for biosimilar and generic medicines. Reference medicines with a combined value of more than USD 650 billion are expected to lose patent protection over the next decade. Sandoz is developing a competitive GLP-1 pipeline across key global markets, addressing each opportunity with a mix of internal capabilities and strategic external partnerships across development and manufacturing. Sandoz is committed to helping millions of patients access critical and potentially life-changing medicines sustainably and affordably, with a leading global portfolio comprising 1,300 quality generics and a further 400 generic assets in various stages of development.
Board Change • May 21High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공고 • May 16Sandoz Group AG Confirms European Commission Approval for Biosimilars Bysumlog® (Insulin Lispro) and Dazparda® (Insulin Aspart), Strengthening Position in DiabetesSandoz Group AG confirms that the European Commission has granted marketing authorisation for Bysumlog (insulin lispro) and Dazparda (insulin aspart). The two biosimilar insulins, for injection in prefilled pens, are developed by Gan & Lee Pharmaceuticals. Bysumlog is approved for the treatment and initial stabilisation of diabetes mellitus in adults and children1, while Dazparda is approved for the treatment of diabetes mellitus in adults, adolescents and children aged one year or more . Both biosimilar insulins have equivalent efficacy and comparable safety to their respective reference medicines, Humalog® and NovoRapid® . Following these approvals, Bysumlog and Dazparda have the potential to increase competition, improve affordability and expand access to insulin treatment options for millions of people living with diabetes across Europe. Diabetes is a chronic condition that occurs when either the pancreas does not produce enough insulin, a hormone that regulates blood glucose, or when the body cannot effectively use the insulin it produces. The disease and its complications can cause blindness, kidney failure, heart attacks, stroke and lower-limb amputation in some patients . An estimated 66 million adults aged 20–79 in Europe live with diabetes and this is projected to rise by 10% to 72 million by 2050, with related healthcare expenditure approaching USD 200 billion . Sandoz entered into an agreement with Gan & Lee in December 2018 to commercialise biosimilar versions of the insulins aspart, lispro and glargine. Under the terms of the agreement, Sandoz will commercialise in Europe and other key territories around the world, while Gan & Lee is responsible for development, manufacturing and supply. The approvals contribute to the continued Sandoz leadership and pioneering legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006. They underscore the company’s commitment to help millions of patients access biologic medicines sustainably and affordably through a global portfolio of 13 biosimilars, supported by an industry-leading pipeline. They further strengthen the Sandoz position in diabetes, while representing another step towards the overall strategic objective of capitalising on a projected approximately USD 320 billion biosimilar market opportunity over the next 10 years .
Board Change • May 05High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공고 • Mar 09Sandoz Group AG, Annual General Meeting, Apr 09, 2026Sandoz Group AG, Annual General Meeting, Apr 09, 2026, at 10:00 W. Europe Standard Time.
New Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Austrian stocks, typically moving 4.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • Feb 28Full year 2025 earnings releasedFull year 2025 results: EPS: US$2.12. Revenue: US$11.2b (up 7.4% from FY 2024). Net income: US$914.0m (up US$914.0m from FY 2024). Profit margin: 8.2% (up from 0% in FY 2024). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in Europe.
공고 • Feb 27Sandoz Group AG announces Annual dividend, payable on April 15, 2026Sandoz Group AG announced Annual dividend of CHF 0.8000 per share payable on April 15, 2026, ex-date on April 13, 2026 and record date on April 14, 2026.
공고 • Feb 26Sandoz Confirms European Commission Approval for Ranluspec®? (Ranibizumab)Sandoz confirmed that the European Commission has granted marketing authorization for Ranluspec. Ranluspec is developed, manufactured and registered by Lupin and was approved based on the review of a comprehensive data package. Ranluspec is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular edema, proliferative diabetic retinopathy, visual impairment due to macular edema secondary to retinal vein occlusion and visual impairment due to choroidal neovascularization. Ranluspec has equivalent efficacy and comparable safety to its reference medicine, Lucentis®?. Around four million people are estimated to have neovascular age-related macular degenerization in France, Germany, Italy, Spain, the UK, the US and Japan3, and between 20% and 35% of people with diabetes in Europe will develop diabetic retinopathy4. The approval paves the way for an expected launch of Ranluspec in the second half of 2026. The announcement builds on the continuing leadership and pioneering legacy Sandoz has established in biosimilars, which began with the introduction of the first biosimilar, Omnitrope®? (somatropin), in 2006. It strengthens the company's position in ophthalmology, following the launch of Afqlir®? (aflibercept) in Europe in 2025 and also represents another step towards the overall Sandoz strategic objective of capitalizing on a projected USD 320 billion biosimilar-market opportunity over the next 10 years. Sandoz and Lupin announced a commercial partnership in August 2025 for the development and commercialization of a ranibizumab biosimilar. Under the terms of the agreement, Sandoz holds exclusive commercialization rights for Ranluspec across the European Union, excluding Germany, and semi-exclusive rights in France. Sandoz is commercializing Epruvy®? (ranibizumab) in Germany under a separate agreement. Lucentis®? is a registered trademark of Genentech Inc.
공고 • Feb 21Sandoz Group AG Receives US FDA Approval to Expand Enzeevu (Aflibercept-Abzv) Label for Multiple Retinal IndicationsSandoz Group AG on February 18, 2026 announced that the US Food and Drug Administration (FDA) has approved an expanded label for Enzeevu (aflibercept-abzv), to include multiple retinal indications. Enzeevu was originally approved by the FDA for the treatment of neovascular (wet) age-related macular degeneration (nAMD) in August 2024. The most recent approval expands the Enzeevu label indications to include macular edema following retinal vein occlusion (RVO), diabetic retinopathy (DR) and diabetic macular edema (DME), along with the previously approved indication of nAMD. This expansion offers retina specialists a clinically-proven aflibercept biosimilar option to treat more patients across these retinal diseases. Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably, with a leading global portfolio comprising 13 biosimilars and a further 27 assets in various stages of development. This approval strengthens the company’s position in ophthalmology, following the acquisition of the US biosimilar Cimerli (ranibizumab-eqrn) in 2024 and the European launch of Afqlir (aflibercept) in 2025. It also represents another step towards the overall strategic objective of capitalizing on a projected approx. USD 320 billion biosimilar market opportunity over the next 10 years . Enzeevu is expected to launch in the US in the fourth quarter of 2026, or earlier under certain circumstances.
Board Change • Feb 05High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공고 • Jan 16Sandoz Confirms European Commission Approval of Ondibta® (Insulin Glargine)Sandoz confirmed that the European Commission has granted marketing authorization for Ondibta® (insulin glargine), a solution for injection in a pre-filled pen developed and registered by Gan & Lee Pharmaceuticals. Ondibta® is approved for the treatment of diabetes mellitus in adults, adolescents and children aged two years and above and is confirmed to match the reference medicine, Lantus® SoloStar® insulin pen, in terms of safety, quality and efficacy. The approval paves the way for an expected launch of Ondibta® by early 2027, which has the potential to increase competition, improve affordability and enhance access to insulin treatment options for people living with diabetes in Europe. Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin, a hormone that regulates blood glucose, or when the body cannot effectively use the insulin that it produces. It can cause blindness, kidney failure, heart attacks, stroke and lower limb amputation. According to latest estimates, there are 66 million adults aged 20-79 living with diabetes in Europe, a figure that is expected to increase 10% by 2050 to 72 million, with related healthcare expenditure approaching USD 200 billion. Sandoz entered into an agreement with Gan & Lee in December 2018 to commercialize biosimilar versions of the insulins glargine, lispro and aspart. Under the terms of the agreement, Sandoz will commercialize in Europe and other key territories around the world, while Gan & Lee is responsible for development, registration, manufacturing and supply. The approval builds on the continuing Sandoz leadership and pioneering legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006. It also strengthens the Sandoz position in diabetes, while representing another step towards the overall strategic objective of capitalizing on a projected USD 320 billion biosimilar-market opportunity over the next 10 years. Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably, with a leading global portfolio comprising 13 biosimilars and a further 27 assets in various stages of development.
Board Change • Jan 07High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Dec 15High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공고 • Dec 03Sandoz Launches Denosumab Biosimilars in Europe, Providing Affordable Treatment Option for Cancer-Related Bone Disease and Osteoporosis for Millions of PatientsSandoz announced the European launch of Wyost ® (denosumab 120 mg) and Jubbonti ® (denosumab 60 mg). The medicines are among the first denosumab biosimilars to launch in Europe and are approved by the European Commission to treat all indications of the reference medicines, Xgeva ® (denosumab 120 mg) and Prolia (denosumab 60 mg). Wyost ® is approved for the treatment of cancer-related bone disease and Jubbonti ® is approved to treat osteoporosis. Wyost ® and Jubbonti ® represent key value drivers for Sandoz and the European launch marks the next major step in advancing the company’s growth strategy. It builds on other key biosimilar launches this year including Wyost ® and Jubbonti ® in the US and the recent launches of Tyruko ® (natalizumab) in the US and Afqlir ® (aflibercept) in Europe. Close to one quarter (4.14 million) of all newly reported cancer cases globally occur in Europe and cancer remains a leading cause of premature death for people aged 30-69 years in most European countries. Nearly all types of cancer can spread to the bone and cause pain and fractures, but cancers that often metastasize there include breast, lung and prostate Wyost ® and Jubbonti ® will be launched across Europe today, with additional rollouts to follow throughout 2026. This launch builds on the continuing Sandoz leadership and pioneering legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006. It further expands the company’s presence in a global reference-medicine market worth a combined ~USD 6.6 billion and reinforces its established position in oncology and immunology. Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably, with a leading global portfolio comprising 13 biosimilars and a further 27 assets in various stages of development. Wyost ® (denosumab 120 mg) and Jubbonti ® (denosumab 60 mg) have been developed as biosimilars to the reference medicines Xgeva and Prolia, respectively. Both medicines contain the same active ingredient (denosumab), a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to RANKL, preventing activation of its receptor, RANK, on the surface of osteoclast precursors and osteoclasts. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function and survival, thereby decreasing bone resorption in cortical and trabecular bone. Wyost ® is indicated in Europe to prevent skeletal related events (SREs; pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone, and to treat adults and skeletally mature adolescents with a giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Jubbonti ® is indicated in Europe to treat osteoporosis in postmenopausal women and in men at increased risk of fractures, bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures and bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.
공고 • Nov 25Sandoz Group AG Launches Afqlir®? (aflibercept) in Europe, Providing Affordable Treatment Option for Patients with Retinal DiseasesSandoz Group AG announced the European launch of Afqlir ® (aflibercept). Afqlir ®, a 2 mg vial kit and pre-filled syringe for intravitreal injection, was approved by the European Commission in November 2024 for the same indications in adult patients as the reference medicine, Eylea ®, namely the treatment of various retinal diseases to prevent disease-related blindness. Studies confirm that Afqlir ® matches the reference medicine in efficacy, safety and pharmacokinetics. Aflibercept is considered a gold standard for treating various neovascular retinal diseases. Conditions like age-related macular degeneration (AMD), retinal vein occlusion (RVO) and diabetic macular edema (DME) are leading causes of vision loss and their global prevalence is increasing. A subtype of age-related macular degeneration (AMD), nAMD is characterized by vision loss in the central zone and is a leading cause of vision impairment in patients over 65 years of age. Although nAMD represents about 10 to 20 percent of all AMD cases, it accounts for 90 percent of severe vision loss linked to AMD. In France, Germany, Italy, Spain, the UK, the US and Japan, around 4.0 million people are estimated to have nAMD. Of these, 2.8 million are diagnosed but only 2.0 million receive treatment. Afqlir ® will be launched across Europe, beginning in the UK, followed by other major markets such as Germany and France, with additional rollouts to follow in 2026. Afqlir ® is one of several biosimilar value drivers for Sandoz and this launch represents another step in advancing the company’s growth strategy, building on major launches this year including Tyruko ® (natalizumab) and Wyost ® (denosumab) and Jubbonti ® (denosumab) in the US. Sandoz is committed to helping million of patients access critical and potentially life-changing biologic medicines sustainably and affordably, with a leading global portfolio comprising 13 biosimilars and a further 27 assets in various stages of development. The launch builds on the existing Sandoz leadership and legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006, and expands the company’s presence in the ~USD 15 billion anti-VEGF ophthalmology market. In September 2025, Sandoz also announced that it had reached an agreement with Regeneron Pharmaceuticals Inc. to resolve all patent disputes between the two companies relating to the US Food and Drug Administration (FDA)-approved aflibercept biosimilar, clearing the path for the launch of Enzeevu™ (aflibercept-abzv) in the US by the end of 2026.
공고 • Nov 16Sandoz Group AG to Report First Half, 2026 Results on Aug 05, 2026Sandoz Group AG announced that they will report first half, 2026 results on Aug 05, 2026
Board Change • Oct 30High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Gilbert Ghostine is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.